Patients’ individual genomes may affect efficacy, safety of gene editing
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people’s cells, and multiple trials are recruiting or in the planning stages. A new study led by Boston Children’s Hospital and the University of Montreal raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous “off target” effect.
The study adds to evidence that gene editing may need to be adapted to each patient’s genome, to ensure there aren’t variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear this week in the Proceedings of the National Academy of Sciences Early Edition (December 11-15).
“Humans vary in their DNA sequences, and what is taken as the ‘normal’ DNA sequence for reference cannot account for all these differences,” says Stuart Orkin, MD, of Dana-Farber Boston Children’s Cancer and Blood Disorders Center and co-corresponding author on the study with Matthew Canver, an MD-PhD student at Harvard Medical School. “We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns.”
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team, led by Orkin, Canver and Samuel Lessard of the University of Montreal, then looked to see whether any of the 7,444 individuals carried DNA sequence variants (“letter changes” or insertions/deletions) in the areas the gRNAs are looking for.
“If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure,” explains Canver, who conceived and led the study in Orkin’s Boston Children’s Hospital lab. “A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy.”
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place — resulting in an edit of a gene or other DNA region that’s not meant to be targeted.
“In rare cases, there was the potential to create very potent ‘off-target’ sites – where CRISPR reagents could bind and cut where they’re not intended to,” says Canver. “If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern.”
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
“The unifying theme is that all these technologies rely on identifying stretches of DNA bases very specifically,” says Canver. “So, a variant that affects the target sequence could reduce guide RNA binding. Variants can also lead to binding at new sites that could potentially cause harm. As these gene-editing therapies continue to develop and start to approach the clinic, it’s important to make sure each therapy is going to be tailored to the patient that’s going to be treated.”
Learn more: Patients’ individual genomes may affect efficacy, safety of gene editing
The Latest on: Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Gene Editing for Inherited Form of Blindness Shows Promise in Phase I/II Trialon May 6, 2024 at 10:01 am
CRISPR gene editing leads to improvements in vision for people with inherited blindness, a recent clinical trial shows.
- Clinical trial shows measurable improvement in inherited blindness after gene therapyon May 6, 2024 at 8:19 am
An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial says.
- First Patient Begins Newly Approved Sickle Cell Gene Therapyon May 6, 2024 at 7:12 am
A 12-year-old boy in the Washington, D.C., area faces months of procedures to remedy his disease. “I want to be cured,” he said.
- Experimental gene therapy restores some vision in patients with inherited blindnesson May 6, 2024 at 6:06 am
For her entire life, college student Olivia Cook had only a small degree of central vision. It was as if she was watching the world through a straw hole, and in dimly lit places, she could not make ...
- CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial showson May 6, 2024 at 6:00 am
Results from a clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants ...
- CRISPR gene editing trial treats inherited blindnesson May 6, 2024 at 6:00 am
They say they hope to cure disease soon. Scientists said they used a human the gene editing tool, CRISPR-Cas9, to restore vision in people with a rare form of inherited or congenital blindness. The ...
- Pioneering CRISPR Gene Editing Trial: 79% of Participants See Improvementon May 6, 2024 at 6:00 am
CRISPR gene editing shows potential in treating blindness, with 79% of trial participants experiencing improved vision. About 79% of clinical trial participants experienced measurable improvement ...
- CRISPR gene therapy improves vision in people with inherited blindnesson May 6, 2024 at 6:00 am
Phase 1/2 trial of Brilliance showed promising results in vision improvement in people with inherited retinal disorders.
- 3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaireon May 2, 2024 at 3:04 am
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body ...
- ‘ChatGPT for CRISPR’ creates new gene-editing toolson April 28, 2024 at 5:00 pm
This week, researchers published details of how they used a generative AI tool called a protein language model — a neural network trained on millions of protein sequences — to design CRISPR ...
via Google News and Bing News